OSBORNE DAVID W 4
4 · Arcutis Biotherapeutics, Inc. · Filed Dec 16, 2020
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Sale
Common Stock
2020-12-14$30.00/sh−15,000$450,000→ 250,533 total
Holdings
- 62,478(indirect: By Trust)
Common Stock
- 62,478(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- [F3]Includes 1,254 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,038 shares on May 31, 2020 and 216 shares on November 30, 2020.
- [F4]The securities are held of record by The Osborne Irrevocable Trust FBO John Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F5]The securities are held of record by The Osborne Irrevocable Trust FBO Sharon Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.